Prasad Kulkarni on the Covishield vaccine
About this episode
Prasad Kulkarni, Medical Director of the Serum Institute of India, discusses his recent phase 2/3 trial on the Covishield vaccine published in eClinicalMedicine, as well as its implications for COVID vaccine development in general.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Get every episode summarized
Each time eClinicalMedicine in conversation with publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from eClinicalMedicine in conversation with
Gita Mishra on an early prediction model for endometriosis risk
eClinicalMedicine in conversation with
Emmanuel Stamatakis on Sleep, Physical Activity and Nutrition changes needed for...
eClinicalMedicine in conversation with
The eCM team on 2025 and 2026
eClinicalMedicine in conversation with
Mahdi Sheikh on pharmaceutical opioid use and subsequent cancer risk
eClinicalMedicine in conversation with